Vera Therapeutics (NASDAQ:VERA) Sets New 12-Month High – Here’s What Happened

Vera Therapeutics, Inc. (NASDAQ:VERA)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $56.05 and last traded at $55.26, with a volume of 481130 shares traded. The stock had previously closed at $53.91.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Pivotal Research set a $73.00 price target on Vera Therapeutics in a research note on Friday, December 5th. TD Cowen boosted their target price on shares of Vera Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday, December 5th. The Goldman Sachs Group increased their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.83.

Vera Therapeutics Trading Up 2.5%

The stock’s 50 day moving average is $35.31 and its 200-day moving average is $27.82. The company has a market cap of $3.53 billion, a P/E ratio of -13.85 and a beta of 1.21. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period last year, the firm earned ($0.85) EPS. Research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Joseph R. Young sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the transaction, the senior vice president directly owned 47,839 shares in the company, valued at $1,390,201.34. The trade was a 23.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the transaction, the director directly owned 5,882 shares in the company, valued at $249,985. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 16.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors have recently modified their holdings of the business. Quantbot Technologies LP bought a new stake in Vera Therapeutics in the 2nd quarter worth about $51,000. Quarry LP boosted its holdings in shares of Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after acquiring an additional 500 shares during the last quarter. AlphaQuest LLC boosted its holdings in shares of Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after acquiring an additional 3,213 shares during the last quarter. Virtus Investment Advisers LLC grew its stake in shares of Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after acquiring an additional 539 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.